Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CTSV | O60911 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31352860 | 0.89 | CTSV (0.50) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL26113307 | 0.89 | CTSV (0.50) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL6361504 | 0.81 | MEN1 (0.56) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL12763816 | 0.81 | MEN1 (0.56) | MEN1KMT2AMAPTLMNATDP1 | |
| SCHEMBL2063806 | 0.79 | MEN1 (0.57) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29444157 | 0.79 | MEN1 (0.57) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL1013111 | 0.79 | MEN1 (0.57) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL26631729 | 0.79 | ALDH1A1 (0.46) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL11922562 | 0.78 | CTSV (0.53) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL18660057 | 0.78 | CTSV (0.50) | MEN1KMT2AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | MEN1 4773/4885KMT2A 3647/4885MAPT 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.